$2.38T
Total marketcap
$72.94B
Total volume
BTC 50.54%     ETH 15.01%
Dominance

Outlook Therapeutics, Inc. 41ON.SG Stock

6.24 EUR {{ price }} 0.000000% {{change_pct}}%
COUNTRY
Germany
Exchange
Stuttgart
Market Cap
147M EUR
LOW - HIGH [24H]
0.31 - 6.24 EUR
VOLUME [24H]
0 EUR
{{ volume }}
P/E Ratio
0
Earnings per share
-3.68 EUR

Outlook Therapeutics, Inc. Price Chart

Outlook Therapeutics, Inc. 41ON.SG Financial and Trading Overview

Outlook Therapeutics, Inc. stock price 6.24 EUR
Previous Close 1.46 EUR
Open 1.55 EUR
Bid 1.55 EUR x 0
Ask 1.7 EUR x 0
Day's Range 1.55 - 1.55 EUR
52 Week Range 0.78 - 1.73 EUR
Volume 0 EUR
Avg. Volume 25 EUR
Market Cap 427.24M EUR
Beta (5Y Monthly) 0.62183
PE Ratio (TTM) N/A
EPS (TTM) -3.68 EUR
Forward Dividend & Yield N/A (N/A)
Ex-Dividend Date N/A
1y Target Est N/A

41ON.SG Valuation Measures

Enterprise Value 360.38M EUR
Trailing P/E N/A
Forward P/E N/A
PEG Ratio (5 yr expected) N/A
Price/Sales (ttm) N/A
Price/Book (mrq) 37.804874
Enterprise Value/Revenue N/A
Enterprise Value/EBITDA -6.747

Trading Information

Outlook Therapeutics, Inc. Stock Price History

Beta (5Y Monthly) 0.62183
52-Week Change 54.25%
S&P500 52-Week Change 20.43%
52 Week High 1.73 EUR
52 Week Low 0.78 EUR
50-Day Moving Average 1.1 EUR
200-Day Moving Average 1.06 EUR

41ON.SG Share Statistics

Avg. Volume (3 month) 25 EUR
Avg. Daily Volume (10-Days) 140 EUR
Shares Outstanding 256.67M
Float 124.54M
Short Ratio N/A
% Held by Insiders 60.70%
% Held by Institutions 10.76%
Shares Short N/A
Short % of Float N/A
Short % of Shares Outstanding N/A

Dividends & Splits

Trailing Annual Dividend Rate 0
Trailing Annual Dividend Yield 0%
5 Year Average Dividend Yield N/A
Payout Ratio 0
Last Split Factor

Financial Highlights

Fiscal Year

Fiscal Year Ends September 30, 2022
Most Recent Quarter (mrq) March 31, 2023
Next Fiscal Year End September 30, 2023

Profitability

Profit Margin 0%
Operating Margin (ttm) 0%
Gross Margin 0%
EBITDA Margin 0%

Management Effectiveness

Return on Assets (ttm) -54.98%
Return on Equity (ttm) -246.29%

Income Statement

Revenue (ttm) N/A
Revenue Per Share (ttm) N/A
Quarterly Revenue Growth (yoy) N/A
Gross Profit (ttm) -42330856 EUR
EBITDA -53412928 EUR
Net Income Avi to Common (ttm) -57201784 EUR
Diluted EPS (ttm) -0.22
Quarterly Earnings Growth (yoy) N/A

Balance Sheet

Total Cash (mrq) 43.63M EUR
Total Cash Per Share (mrq) 0.17 EUR
Total Debt (mrq) 31.84M EUR
Total Debt/Equity (mrq) 303.57 EUR
Current Ratio (mrq) 1.219
Book Value Per Share (mrq) 0.041

Cash Flow Statement

Operating Cash Flow (ttm) -48365792 EUR
Levered Free Cash Flow (ttm) -27853590 EUR

Profile of Outlook Therapeutics, Inc.

Country Germany
State NJ
City Iselin
Address Building F
ZIP 08852
Phone 609 619 3990
Website https://www.outlooktherapeutics.com
Industry Biotechnology
Sector(s) Healthcare
Full Time Employees 17

Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with IPCA Laboratories Limited; Laboratorios Liomont, S.A. de C.V.; BioLexis Pte. Ltd.; and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.

Q&A For Outlook Therapeutics, Inc. Stock

What is a current 41ON.SG stock price?

Outlook Therapeutics, Inc. 41ON.SG stock price today per share is 6.24 EUR.

How to purchase Outlook Therapeutics, Inc. stock?

You can buy 41ON.SG shares on the Stuttgart exchange. Contact your financial advisor to select a broker.

What is the ticker symbol for Outlook Therapeutics, Inc.?

The stock symbol or ticker of Outlook Therapeutics, Inc. is 41ON.SG.

Which industry does the Outlook Therapeutics, Inc. company belong to?

The Outlook Therapeutics, Inc. industry is Biotechnology.

How many shares does Outlook Therapeutics, Inc. have in circulation?

The max supply of Outlook Therapeutics, Inc. shares is 23.56M.

What is Outlook Therapeutics, Inc. Price to Earnings Ratio (PE Ratio)?

Outlook Therapeutics, Inc. PE Ratio is now.

What was Outlook Therapeutics, Inc. earnings per share over the trailing 12 months (TTM)?

Outlook Therapeutics, Inc. EPS is -3.68 EUR over the trailing 12 months.

Which sector does the Outlook Therapeutics, Inc. company belong to?

The Outlook Therapeutics, Inc. sector is Healthcare.